- Trials with a EudraCT protocol (8)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
8 result(s) found for: Tendon reflex.
Displaying page 1 of 1.
EudraCT Number: 2008-001218-26 | Sponsor Protocol Number: TRO19622 CL E Q 1204-1 | Start Date*: 2008-06-19 | |||||||||||
Sponsor Name:TROPHOS SA | |||||||||||||
Full Title: A double blind, placebo controlled study of the effect of 330mg QD of TRO19622 in the treatment of Chemotherapy Induced Peripheral Neuropathy. | |||||||||||||
Medical condition: Symptoms of chemotherapy induced peripheral neuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000636-15 | Sponsor Protocol Number: 12/201/02 | Start Date*: 2015-05-27 |
Sponsor Name:Bangor University | ||
Full Title: A randomised controlled trial of adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica. | ||
Medical condition: Sciatica is a symptom defined as unilateral, well-localised leg pain, with a sharp, shooting or burning quality, that approximates to the dermatomal distribution of the sciatic nerve down the poste... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-001238-32 | Sponsor Protocol Number: ADVL1622 | Start Date*: 2019-09-26 |
Sponsor Name:National Cancer Institute Cancer Therapy Evaluation | ||
Full Title: Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors | ||
Medical condition: Ewing sarcoma, Rhabdomyosarcoma, Non rhabdomyosarcoma, Wilms Tumor, Osteosarcoma and Other Rare Tumors | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-001449-26 | Sponsor Protocol Number: 6603/1132 | Start Date*: 2015-01-22 | |||||||||||
Sponsor Name:Seikagaku Corporation | |||||||||||||
Full Title: A Multicenter, Open-label Study of SI-6603 in Patients with Lumbar Disc Herniation (Phase III) | |||||||||||||
Medical condition: Lumbar disc herniation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003447-29 | Sponsor Protocol Number: DAP-PEDBAC-11-02 | Start Date*: 2013-06-11 | |||||||||||
Sponsor Name:Cubist Pharmaceuticals, Inc. | |||||||||||||
Full Title: A COMPARATIVE EVALUATION OF THE SAFETY AND EFFICACY OF DAPTOMYCIN VERSUS STANDARD OF CARE IN PEDIATRIC SUBJECTS TWO - SEVENTEEN YEARS OF AGE WITH BACTEREMIA CAUSED BY STAPHYLOCOCCUS AUREUS. | |||||||||||||
Medical condition: Bacteremia caused by Staphylococcus Aureus. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) ES (Completed) HU (Completed) GR (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002523-42 | Sponsor Protocol Number: D5680C00002 | Start Date*: 2018-10-22 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled, dose-response study of the efficacy and safety of MEDI7352 in subjects with painful diabetic neuropathy | |||||||||||||
Medical condition: Painful diabetic neuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) PL (Prematurely Ended) HU (Prematurely Ended) DK (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007974-39 | Sponsor Protocol Number: AIO-KRK-0207 | Start Date*: 2009-08-04 | ||||||||||||||||
Sponsor Name:AIO-Studien-gGmbH | ||||||||||||||||||
Full Title: Randomized three arm phase III trial on induction treatment with a fluoropyrimidine-, oxaliplatin- and bevacizumab-based chemotherapy for 24 weeks followed by maintenance treatment with a fluoropyr... | ||||||||||||||||||
Medical condition: Histologically confirmed and inoperable or irresectable metastatic colorectal cancer (stage IV) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-002934-35 | Sponsor Protocol Number: ADVL1615 | Start Date*: 2021-05-21 | |||||||||||
Sponsor Name:Children's Oncology Group | |||||||||||||
Full Title: A Phase 1 Study of Pevonedistat (MLN4924, IND# 136078) a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory ... | |||||||||||||
Medical condition: This trial studies the side effects and best dose of pevonedistat when given together with irinotecan and temozolomide in treating patients with solid tumors or lymphoma that have come back after a... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
